头颈部癌相关血栓的临床致病因素研究进展

琦 贺(新疆医科大学第一附属医院（附属口腔医院）口腔颌面肿瘤外科，中国)
乌拉尔别克 阿依达娜·(新疆医科大学第一附属医院（附属口腔医院）口腔颌面肿瘤外科，中国)
加帕尔 阿曼妮萨罕·(新疆医科大学第一附属医院（附属口腔医院）口腔颌面肿瘤外科，中国)
彬 凌(新疆医科大学第一附属医院（附属口腔医院）口腔颌面肿瘤外科，中国 新疆维吾尔自治区口腔医学研究所，中国)

摘要

癌症与血栓的形成有关，血栓形成对癌症的增殖和延伸也有影响。癌症相关静脉血栓栓塞发病机制主要有肿瘤细胞在其发生发展的过程中通过多种途径打破机体的凝血与纤溶系统的平衡，使机体处于高凝状态；然后与患者自身、与恶性肿瘤相关以及肿瘤治疗有关的因素多种因素复杂相互作用的结果。由于其发病机制复杂，论文就头颈部癌相关静脉血栓的临床致病因素进行如下综述，通过讨论头颈部癌症患者血栓的发病机制和临床致病因素，从而在临床实际应用中更好进行VTE的预防，加强风险评估、提高对VTE相关因素的认知，做好病人及医护人员的宣教，对患者进行个体化管理及抗凝治疗，治疗后密切的随访和定期复查，从而改善患者生活治疗，延长生存时间，降低头颈部癌相关VTE的发生。

关键词

癌症相关血栓；头颈部癌；临床致病因素

参考

Leiva O. Cancer and thrombosis: new insights to an old problem[J]. Med-Vasc,2020,45(6):8-16.

赵纪春 , 吴洲鹏 , 郭强 . 肿瘤相关静脉血栓栓塞症治疗指南解读[J]. 中国普外基础与临床杂志 ,2020,27(4):407-411.

Citla Sridhar D, Abou-Ismail MY, Ahuja SP. Central venous

catheter-related thrombosis in children and adults[J]. Thromb Res,2020(187):103-112.

Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw,2021,19(10):1181-1201.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249.

Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study[J]. Blood,2021,137(14):1959-1969.

Thai L, McCarn K, Stott W, et al. Venous thromboembolism

in patients with head and neck cancer after surgery[J]. Head Neck,2013,35(1):4-9.

王乔宇 , 武明芬 , 柳鑫 , 等 .2021 中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南 [J]. 中国临床药理学杂志,2021,37(21):2999-3016.

Kushner A, West WP, Pillarisetty LS. Virchow Triad. 2021

Sep 14. In: StatPearls[J]. Treasure Island (FL): StatPearls Publishing,2022(1):30969519.

Trousseau A. Plegmasia alba dolens[J]. Lectures on clinical

medicine, delivered at the Hotel-Dieu, Paris,1865(5):281-332.

Zhen C, Wang Y, Wang H, et al. Multiple cerebral infarction linked to underlying cancer: a review of Trousseau syndrome-related cerebral infarction[J]. Br J Hosp Med (Lond),2021,82(5):1-7.

Tipirneni KE, Bauter L, Arnold MA, et al. Association of ProlongedDuration Chemoprophylaxis With Venous Thromboembolism in High-risk Patients With Head and Neck Cancer[J]. JAMA Otolaryngol Head Neck Surg, 202,147(4):320-328.

Clayburgh DR, Stott W, Cordiero T, et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgeryr[J]. JAMA Otolaryngol Head Neck Surg, 2013,139(11):1143-1150.

LYMAN G H, KUDERER N M. Clinical practice guidelines for

the treatment and prevention of cancer-associated thrombosis[J]. Thromb Res,2020,191(1):79-84.

肖剑 , 宋业勋 , 谭国林 . 头颈恶性肿瘤术后静脉血栓栓塞症患者临床分析 [J]. 临床耳鼻咽喉头颈外科杂志 ,2021,35(9):779-783.

赵纪春 , 吴洲鹏 , 郭强 , 等 . 肿瘤相关静脉血栓栓塞症治疗指南解读 [J]. 中国普外基础与临床杂志 ,2020,27(4):407-411.

Vlodavsky I, Gross-Cohen M, Weissmann M, er al.Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression[J]. Trends Biochem. Sci,2018(43):18-31.

Kim, Ann S. “Mechanisms and biomarkers of cancer-associated thrombosis.”[J]. Translational research : the journal of laboratory and clinical medicine vol,2020(225):33-53.

Angchaisuksiri, Pantep. “Venous thromboembolism in Asia

and worldwide: Emerging insights from GARFIELD-VTE.”[J]. Thrombosis research vol, 2021(201):63-72.

Nasser, Nicola J. “Potential Mechanisms of Cancer-Related

Hypercoagulability.”[J]. Cancers vol,. 2020,12(3):566.

Hamza MS, Mousa SA. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management[J]. Clin Appl Thromb Hemost, 2020(26):1076029620954282.

Temraz S, Moukalled N, Gerotziafas GT ,et al. Association

between Radiotherapy and Risk of Cancer Associated Venous

Thromboembolism: A Sub-Analysis of the COMPASS-CAT Study[J]. Cancers (Basel),2021,13(5):1-10.

Guy JB, Bertoletti L, Magne N ,et al. Venous thromboembolism in radiation therapy cancer patients:Findings from the RIETE registry[J]. Crit Rev Oncol Hematol,2017(113):83-89.

Leith JT, Hercbergs A, Kenney S, et al. Activation of tumor cell integrin avb3byradiationandreversalof activation by chemically modified tetraiodothyroacetic acid (tetrac)[J]. Endocr Res, 2018,43(4):215-219.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v5i12.12310